New treatment targets multiple myeloma cancer; Check out how it works
For patients suffering from the type of cancer multiple myeloma resistant to available treatments, the National Health Surveillance Agency (Anvisa) approved, this Friday, 01, a new treatment against the disease. It is a therapy based on modified T cells.in order to “express chimeric antigen receptors (CAR)”.
rare cancer, multiple myeloma causes an uncontrolled proliferation of plasma cells – white blood cells that produce antibodies. “When these cells become malignant (cancer), they no longer protect the body from infections and produce abnormal proteins that can cause problems affecting the kidneys, bones or blood system”explains the agency.
HOW DOES THE NEW CANCER TREATMENT WORK?
The gene treatment product is Carvykti, which consists of collection of the patient’s T cells that will be altered to kill the cancer cells. That’s why the treatment is considered personalized. According to Anvisa, “97.9% of study patients responded positively to treatment” and “among the 95 patients who responded positively, the median duration of response was 21.8 months”time that there was no indication of the return of the cancer.
Therapy with Carvykti is part of the gene type ex vivothat is, introduction of the target gene in the laboratory and in specific cells. “Later, a product is formulated with suspension of these modified cells, which will then be administered to the patient”explains Anvisa.
Source: Recreio
